Scarica l'app Stockscreener
0.00
100.00%
-15.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$15.02
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$1.48B
Reddito:
$11.40B
Utile/perdita netta:
$-95.73M
Rapporto P/E:
0.00
EPS:
-2.45
Flusso di cassa netto:
$-64.37M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$15.29
Definium Therapeutics Inc Stock (MNMD) Company Profile
Nome
Definium Therapeutics Inc
Settore
Industria
Telefono
212-220-6633
Indirizzo
ONE WORLD TRADE CENTER, NEW YORK
Compare MNMD vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MNMD
Definium Therapeutics Inc
|
0.00 | 1.48B | 11.40B | -95.73M | -64.37M | -2.45 |
VRTX
Vertex Pharmaceuticals Inc
|
447.26 | 113.44B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
777.25 | 81.68B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
743.12 | 45.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.73 | 43.88B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.86 | 35.25B | 606.42M | -1.28B | -997.58M | -6.403 |
Definium Therapeutics Inc Stock (MNMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-01-30 | Iniziato | Jefferies | Buy |
| 2025-10-13 | Iniziato | Needham | Buy |
| 2025-08-04 | Ripresa | Oppenheimer | Outperform |
| 2025-01-28 | Iniziato | Evercore ISI | Outperform |
| 2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
| 2024-10-14 | Ripresa | Leerink Partners | Outperform |
| 2024-07-24 | Iniziato | ROTH MKM | Buy |
| 2024-05-29 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-15 | Iniziato | Leerink Partners | Outperform |
| 2023-12-05 | Iniziato | Canaccord Genuity | Buy |
| 2022-12-09 | Ripresa | ROTH Capital | Buy |
| 2022-11-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-08-26 | Iniziato | Oppenheimer | Outperform |
| 2022-08-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-05-04 | Iniziato | ROTH Capital | Buy |
| 2021-06-28 | Iniziato | Maxim Group | Buy |
Mostra tutto
Definium Therapeutics Inc Borsa (MNMD) Ultime notizie
Definium Therapeutics (NASDAQ:DFTX) Sets New 52-Week HighHere's Why - marketbeat.com
Definium Therapeutics stock hits 52-week high at 19.78 USD - investing.com
New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States - BioSpace
Definium Therapeutics (DFTX) Study Highlights Rising GAD Rates i - GuruFocus
Anxiety disorder prevalence rises to 6.6% in U.S., study finds By Investing.com - Investing.com Australia
Anxiety disorder prevalence rises to 6.6% in U.S., study finds - investing.com
Definium Therapeutics Inc (DFTX) Stock Price Quote Today & Current Price Chart - capital.com
Definium Therapeutics Announces New Employee Inducement Grants - ca.finance.yahoo.com
A Look At Definium Therapeutics (DFTX) Valuation As Investor Day Highlights Late Stage DT120 ODT Pipeline - Sahm
Definium Therapeutics, Inc. (NASDAQ:DFTX) Short Interest Update - Defense World
symbol__ Stock Quote Price and Forecast - CNN
Definium Therapeutics Insider Sold Shares Worth $451,241, According to a Recent SEC Filing - marketscreener.com
Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026 - BioSpace
Definium Therapeutics CMO Karlin sells $148k in shares By Investing.com - Investing.com Australia
Definium Therapeutics CEO Barrow sells $451k in shares By Investing.com - Investing.com India
Definium Therapeutics CEO Barrow sells $451k in shares - Investing.com
Definium Therapeutics CMO Karlin sells $148k in shares - Investing.com
Definium Therapeutics chief legal officer sells $197k in shares - Investing.com
Definium Therapeutics chief legal officer sells $197k in shares By Investing.com - Investing.com UK
Definium (NASDAQ: DFTX) CMO sells shares to cover RSU tax - Stock Titan
Tax-cover sale by Definium (DFTX) legal chief totals 10,702 shares - Stock Titan
Definium Therapeutics (DFTX) CEO share sale covers RSU tax withholding - Stock Titan
Definium Therapeutics brings Investor and Analyst Day event to New York - Traders Union
Robert Barrow files to sell 24,431 DFTX shares (DFTX) - Stock Titan
Affiliate sale notice for DFTX (NASDAQ: DFTX) — 8,018 shares reported - Stock Titan
Mark Sullivan to sell 10,702 shares (DFTX) under registered plan - Stock Titan
A Look At Definium Therapeutics (DFTX) Valuation After Its Recent Name Change And Share Price Momentum - Yahoo Finance
Definium Therapeutics Inc (DFTX) Says Cash Enough to Fund Operations into 2028 - Insider Monkey
9 Best Psychedelic Stocks to Buy in 2026 - Insider Monkey
Biotech Firm Developing LSD-Based Psychiatric Treatments Moves to Dismiss Trade Secrets Lawsuit, Calls Claims by Former Clinical Trial Vendor Legally Deficient - USA Herald
A Look At Definium Therapeutics (DFTX) Valuation After Strong Recent Share Price Momentum - Sahm
Definium Therapeutics (NASDAQ:DFTX) Sets New 12-Month HighHere's Why - MarketBeat
Definium Therapeutics stock hits 52-week high at 19.66 USD By Investing.com - Investing.com South Africa
Definium Therapeutics stock hits 52-week high at 19.66 USD - Investing.com
Definium Therapeutics Teases 3 Key DT-120 Data Readouts This Year, Highlights De-Risked Phase 3 Design - MarketBeat
Superstring Capital's Definium Therapeutics Investment: Q4 2025 PositionNews and Statistics - IndexBox
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names - AOL.com
DFTX: Definium Therapeutics, Inc.Detailed Earnings Estimates - Zacks Investment Research
DFTX: Pivotal phase III data for DT-120 in GAD and MDD expected this year, targeting broad market impact - TradingView
Definium Therapeutics, Inc. (NASDAQ:DFTX) Q4 2025 earnings call transcript - MSN
Definium Therapeutics stock hits 52-week high at 18.71 USD By Investing.com - Investing.com Nigeria
Boxer Capital Management LLC Takes Position in Definium Therapeutics, Inc. $DFTX - MarketBeat
Definium Therapeutics Teases Phase III DT120 Data for Anxiety, Depression at Leerink Conference - MarketBeat
Commodore Capital LP Lowers Holdings in Definium Therapeutics, Inc. $DFTX - MarketBeat
Ally Bridge Group NY LLC Sells 364,728 Shares of Definium Therapeutics, Inc. $DFTX - MarketBeat
Definium Therapeutics Inc Azioni (MNMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Definium Therapeutics Inc Azioni (MNMD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sullivan Mark | Chief Legal Officer |
Mar 25 '26 |
Sale |
18.47 |
10,702 |
197,666 |
271,079 |
| Barrow Robert | Chief Executive Officer |
Mar 25 '26 |
Sale |
18.47 |
24,431 |
451,241 |
752,454 |
1.52%
0.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):